CO2021016471A2 - Inhibidores de kcnt1 y métodos de uso - Google Patents

Inhibidores de kcnt1 y métodos de uso

Info

Publication number
CO2021016471A2
CO2021016471A2 CONC2021/0016471A CO2021016471A CO2021016471A2 CO 2021016471 A2 CO2021016471 A2 CO 2021016471A2 CO 2021016471 A CO2021016471 A CO 2021016471A CO 2021016471 A2 CO2021016471 A2 CO 2021016471A2
Authority
CO
Colombia
Prior art keywords
kcnt1
methods
inhibitors
disease
disorder
Prior art date
Application number
CONC2021/0016471A
Other languages
English (en)
Inventor
Botella Gabriel Martinez
Andrew Mark Griffin
Paul S Charifson
Kiran Reddy
Michael Kristopher Mathieu Kahlig
Brian Edward Marron
Original Assignee
Praxis Prec Medicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Praxis Prec Medicines Inc filed Critical Praxis Prec Medicines Inc
Publication of CO2021016471A2 publication Critical patent/CO2021016471A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención está dirigida, en parte, a compuestos y composiciones útiles para prevenir y/o tratar una enfermedad o trastorno neurológico, una enfermedad o afección relacionada con excitabilidad neuronal excesiva y/o una mutación de ganancia de función en un gen (por ejemplo, KCNT1). También se proporcionan en la presente descripción métodos para tratar una enfermedad o trastorno neurológico, una enfermedad o afección relacionada con excitabilidad neuronal excesiva y/o una mutación de ganancia de función en un gen tal como KCNT1.
CONC2021/0016471A 2019-05-03 2021-12-02 Inhibidores de kcnt1 y métodos de uso CO2021016471A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962842849P 2019-05-03 2019-05-03
US202062982864P 2020-02-28 2020-02-28
PCT/US2020/031046 WO2020227101A1 (en) 2019-05-03 2020-05-01 Kcnt1 inhibitors and methods of use

Publications (1)

Publication Number Publication Date
CO2021016471A2 true CO2021016471A2 (es) 2022-04-08

Family

ID=73051241

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0016471A CO2021016471A2 (es) 2019-05-03 2021-12-02 Inhibidores de kcnt1 y métodos de uso

Country Status (17)

Country Link
US (1) US20220259193A1 (es)
EP (1) EP3962481A4 (es)
JP (1) JP2022531388A (es)
KR (1) KR20220016086A (es)
CN (1) CN114269340A (es)
AU (1) AU2020267356A1 (es)
BR (1) BR112021022067A2 (es)
CA (1) CA3139063A1 (es)
CL (1) CL2021002877A1 (es)
CO (1) CO2021016471A2 (es)
EC (1) ECSP21087884A (es)
IL (1) IL287768A (es)
MX (1) MX2021013421A (es)
PE (1) PE20220016A1 (es)
SA (1) SA521430751B1 (es)
SG (1) SG11202112158YA (es)
WO (1) WO2020227101A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022530989A (ja) * 2019-05-03 2022-07-05 プラクシス プレシジョン メディシンズ， インコーポレイテッド Ｋｃｎｔ１阻害剤および使用する方法
US20230373937A1 (en) * 2020-09-09 2023-11-23 University Of Virginia Patent Foundation Inhibitors of spinster homolog 2 (spns2) for use in therapy
US11773088B2 (en) 2020-11-02 2023-10-03 Praxis Precision Medicines, Inc. KCNT1 inhibitors and methods of use
TW202227424A (zh) * 2020-11-27 2022-07-16 大陸商瑞石生物醫藥有限公司 芳基或雜芳基取代５員芳雜環化合物及其用途
US20240043415A1 (en) * 2020-12-22 2024-02-08 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
WO2022231873A1 (en) * 2021-04-29 2022-11-03 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
WO2022231872A1 (en) * 2021-04-29 2022-11-03 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
WO2023211850A1 (en) * 2022-04-25 2023-11-02 Praxis Precision Medicines, Inc. Kcnt1 inhibitors comprising an isoxazole or oxadiazole core and methods of use
WO2023239839A1 (en) * 2022-06-08 2023-12-14 Praxis Precision Medicines, Inc. Kcnt1 inhibitors comprising an isoxazole or oxadiazole core and methods of use

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
TW200301698A (en) * 2001-12-21 2003-07-16 Bristol Myers Squibb Co Acridone inhibitors of IMPDH enzyme
JP2005060255A (ja) * 2003-08-20 2005-03-10 Nippon Nohyaku Co Ltd カルボキサミド類及びこれを有効成分とする有害生物防除剤
US7585881B2 (en) * 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
EP2044061A2 (en) * 2006-07-20 2009-04-08 Mehmet Kahraman Benzothiophene inhibitors of rho kinase
MX355945B (es) * 2013-03-14 2018-05-07 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante.
US10538516B2 (en) * 2015-03-25 2020-01-21 National Center For Geriatrics And Gerontology Oxadiazole derivative and pharmaceutical containing same
EP3438091A4 (en) * 2016-03-30 2019-11-27 Ajinomoto Co., Inc. CONNECTION WITH INCREASING ACTIVITY FOR ACTION OF GLUCAGON LIKE PEPTIDE-1 RECEPTOR
WO2018187480A1 (en) * 2017-04-04 2018-10-11 Praxis Precision Medicines, Inc. Compounds and their methods of use

Also Published As

Publication number Publication date
IL287768A (en) 2022-01-01
SG11202112158YA (en) 2021-12-30
CN114269340A (zh) 2022-04-01
CA3139063A1 (en) 2020-11-12
ECSP21087884A (es) 2022-01-31
SA521430751B1 (ar) 2024-02-01
WO2020227101A1 (en) 2020-11-12
EP3962481A4 (en) 2023-03-22
JP2022531388A (ja) 2022-07-06
CL2021002877A1 (es) 2022-08-12
KR20220016086A (ko) 2022-02-08
PE20220016A1 (es) 2022-01-11
AU2020267356A1 (en) 2022-01-06
EP3962481A1 (en) 2022-03-09
MX2021013421A (es) 2022-02-11
US20220259193A1 (en) 2022-08-18
BR112021022067A2 (pt) 2022-05-17

Similar Documents

Publication Publication Date Title
CO2021016469A2 (es) Inhibidores de kcnt1 y métodos de uso
ECSP21087884A (es) Inhibidores de kcnt1 y métodos de uso
MX2022004101A (es) Composiciones de oligonucleotidos y metodos de uso de las mismas.
MA43131B1 (fr) Compositions et procédés d'inhibition de l'activité de l'arginase
DOP2020000154A (es) Inhibidores pd-1/pd-l1
UY38613A (es) Inhibidores de la proteína tirosina fosfatasa y mètodos de uso de los mismos
TN2018000213A1 (en) Compounds useful as kinase inhibitors
CO2017013234A2 (es) Mezcla para tratar fertilizantes que contienen urea
PH12018500587A1 (en) Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer
ECSP16067303A (es) Heteroarilos y usos de estos
BR112022019041A2 (pt) Inibidores de kcnt1 e métodos de uso
UY36601A (es) Inhibidores de la función enzimática de la indolamina-2,3-dioxigenasa (ido) y composiciones farmacéuticas que los contienen
CO2021000447A2 (es) Inhibidores de proteína tirosina fosfatasa y sus métodos de uso
ATE448207T1 (de) Mitotische kinesin-hemmer
DE60312516D1 (de) Inhibitoren von mitotischem kinesin
MX2020003594A (es) Inhibidores de la quinasa p38 que reducen la expresión de dux4 y de los genes corriente abajo para el tratamiento de fshd.
ECSP23057264A (es) Inhibidores de cdk2 y métodos de uso de los mismos
EA202092748A1 (ru) Модуляторы экспрессии apol1
CO2021001219A2 (es) Benzimidazoles sustituidos como inhibidores de pad4
BR112022005895A2 (pt) Inibidores de aldose redutase para tratamento de deficiência de fosfomanomutase 2
CL2023003811A1 (es) Oligonucleótidos antisentido pikfyve
BR112022017191A2 (pt) Inibidores de kcnt1 e métodos de uso
MX2023000360A (es) Inhibidores de kcnt1 y metodos de uso.
PE20201349A1 (es) Moduladores de la expresion de ezh2
AR129088A1 (es) INHIBIDORES DE PI3Ka